Skip to contentS
Sarepta Therapeutics, Inc.
S
SRPTSarepta Therapeutics, Inc. Q2 2025 · 10-Q
Revenue$513.12M$513.12M+42.3% vs Q2 2024 Net Income$196.89M$196.89M+2,947.9% vs Q2 2024 EPS Diluted$1.89$1.89+2,600.0% vs Q2 2024 Gross Profit$360,565,000+14.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
Operating Cash Flowderived$261,337,000+1,649.0% Free Cash Flowderived$229,541,000N/M Margins · derivedGross margin70.3%−17.4 pt vs Q2 2024
Operating margin22.5%+22.7 pt vs Q2 2024
Net margin38.4%+36.6 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 6, 2025 · 37 d after period end